---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000153"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:40:08.515788+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant CMO Michael Geffner departs; consulting through April 2026

## Summary
- Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.
- Departure is part of R&D leadership restructuring under CEO Eric Venker.
- Severance per existing employment agreement; consulting services through April 30, 2026.
- Outstanding equity awards continue vesting during consulting period; accelerated vesting on change in control.
- Option exercise period extended to nine months after consulting ends or original expiration, whichever earlier.

## SEC filing metadata
- accession: 0001764013-25-000153
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/0001764013-25-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/imvt-20251121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000153
- JSON: https://secwatch.observer/filing/0001764013-25-000153.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.